Study of a new drug for advanced solid tumors
Treatments studied
This trial is testing an investigational drug called ITR-251 in people with advanced solid tumors that have progressed after standard treatments. The study aims to see if the drug is safe and effective, and it includes a part specifically for men with a certain type of prostate cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You need to have an advanced or metastatic solid tumor that has gotten worse despite standard treatments.
- You should be able to care for yourself (ECOG score 0 or 1).
- Your blood counts and liver, kidney, and heart function must be within acceptable ranges.
- If you have prostate cancer, you must be on a specific type of hormone therapy (ARPi) and have rising PSA levels.
- You cannot have certain tumors like brain cancer, liver cancer, or stomach cancer, and you must not have brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug, GLR2037, for men with advanced prostate cancer that has spread to the bones or soft tissue and has progressed despite prior treatments. The drug may help slow the cancer's growth.
This trial tests a new drug called INR731, given by mouth, for men with prostate cancer that has spread to other parts of the body. The study will check if the drug is safe and how well it works, either alone or combined with other prostate cancer medicines.
This trial tests a new drug called INV-9956 in men with advanced prostate cancer that no longer responds to hormone therapy and has spread to other parts of the body. It aims to see if the drug is safe and effective.
This trial tests a new drug called RPTR-1-201 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
This trial tests an experimental drug called ITC-6146RO for people with advanced or metastatic cancer who have run out of standard treatment options. The drug is given to see if it can shrink tumors or slow cancer growth.
This study tests a new targeted therapy called inavolisib for men with advanced, hormone-resistant prostate cancer that has spread. The drug may work by blocking a specific pathway that helps cancer grow. Participants must have already tried one second-generation hormone therapy and have a tumor sample available for testing.
Hear when a new Solid Tumor Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.